| Basics |
Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Inc is a specialty pharmaceutical company engaged in development and commercialization of therapeutic products for markets using patented or proprietary formulations and modified drug delivery technology.
|
| IPO Date: |
June 9, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$21.8M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.07 | 4.32%
|
| Avg Daily Range (30 D): |
$0.07 | 5.35%
|
| Avg Daily Range (90 D): |
$0.06 | 4.46%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.57M |
| Avg Daily Volume (30 D): |
.51M |
| Avg Daily Volume (90 D): |
.61M |
| Trade Size |
| Avg Trade Size (Sh.): |
393 |
| Avg Trade Size (Sh.) (30 D): |
253 |
| Avg Trade Size (Sh.) (90 D): |
256 |
| Institutional Trades |
| Total Inst.Trades: |
45 |
| Avg Inst. Trade: |
$2.78M |
| Avg Inst. Trade (30 D): |
$6.8M |
| Avg Inst. Trade (90 D): |
$6.8M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$6.35M |
| Avg Closing Trade (30 D): |
$6.8M |
| Avg Closing Trade (90 D): |
$6.8M |
| Avg Closing Volume: |
149.91K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-4.98
|
$-.8
|
$-1.27
|
|
Diluted EPS
|
$-4.98
|
$-.8
|
$-1.27
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -42.07M
|
$ -9.2M
|
$ -11.51M
|
|
Operating Income / Loss
|
$ -41.14M
|
$ -8.79M
|
$ -11.26M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -23.23M
|
$ M
|
$
|
|
PE Ratio
|
|
|
|
| Splits |
|
Nov 26, 2024:
1:25
|
|
Jun 09, 2017:
1:15
|
|
Sep 12, 2014:
5:8
|
|
|
|
